Resources

Pioneer Group – the company leading the regeneration of the Grafton Centre – has announced Cambridge-based Envision Health as the winner of its first accelerator programme, aimed at supporting the city’s early-stage tech companies.

Chris Molloy on the Budget; Wellcome Genome Campus; AbbVie; engagement with NICE and MHRA; rare conditions policy; and clinical trials

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

As Most Favoured Nation (MFN) drug pricing policies increase uncertainty around future drug revenues, early-stage biotech companies face greater scrutiny from investors and potential partners.

Chris Molloy, CEO of the BioIndustry Association (BIA), responds to Budget 2026

AI-powered analysis of Phase 3 CHARM trial suggests that Brainomix non-contrast CT (NCCT) technology may help identify severe stroke patients more likely to benefit from CIRARA, supporting more precise patient selection and the design of future stroke trials.

One North Quay, a 23-storey science, technology and innovation campus at Canary Wharf, has reached its full height.

This week, imphatec Ltd. has announced the close of an oversubscribed £1.5M seed round led by SynBioVen, with further participation from angel investors. imphatec is a British synthetic biology pharmaceutical company developing the first customisable-dose subcutaneous implant platform to treat chronic conditions.

Medannex Ltd (Edinburgh) today announced the presentation of updated clinical data from Module 1 of the ongoing ATTAINMENT study of MDX-124 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.

Q3 UK biotech financing; Budget calls; early-stage funding gap; faster clinical trials; connecting Government and industry; digital and AI skills webinar

UK biotech venture capital investment reached £270 million, up 44% from £187 million in Q3 2025, according to new figures from the BioIndustry Association (“BIA”).

Reproducibility starts where setpoints end: in the control strategy that defines how your process actually runs

Quell Therapeutics announced that QEL-005, its CD19 B-cell activated Phenotype-Locked™ engineered nTreg therapy, has advanced to the second planned dose cohort in the CHILL Phase 1/2 clinical study.

Industry leaders gathered at Discovery Park on 14 October for The Lab of the Future & Green Chemistry Innovation, an event exploring pharmaceutical AI, automation and green chemistry, with speakers urging the industry to unite to share learnings and knowledge.

The technology set to transform data in life sciences

NRG Therapeutics announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.

Brainomix, announced the publication of new data from the REVISE PPF multicenter observational study demonstrating the potential of quantitative CT.